alexa Development of tumor B-cell lymphocyte hybridoma (TBH) autovaccination. Results of a phase I-II clinical trial.
Neurology

Neurology

Brain Disorders & Therapy

Author(s): Moviglia GA

Abstract Share this page

Abstract To improve patient immune recognition of autologous tumor cells, we have developed a tumor B-cell lymphocyte hybridoma (TBH) autovaccination protocol. This approach is based on immunization of a cancer patient with a hybridoma cell suspension derived from the fusion of autologous activated B-cells and autologous cancer cells. This hybrid allows the host immune system to recognize and destroy oncocytes with low toxicity and high specificity. Of 21 treated patients with very advanced diseases, six complete responses and four partial responses were achieved. Overall, survival was prolonged. Side-effects and combination therapies with IL2, IL6 and gamma I/FN are discussed in this paper. Breast and colon cancer seem to be sensitive to this therapy.
This article was published in Transfus Sci and referenced in Brain Disorders & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords